JP2009528346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009528346A5 JP2009528346A5 JP2008557241A JP2008557241A JP2009528346A5 JP 2009528346 A5 JP2009528346 A5 JP 2009528346A5 JP 2008557241 A JP2008557241 A JP 2008557241A JP 2008557241 A JP2008557241 A JP 2008557241A JP 2009528346 A5 JP2009528346 A5 JP 2009528346A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- agent
- cell
- chemotherapeutic agent
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 102100032500 40S ribosomal protein S27-like Human genes 0.000 claims 5
- 101000731896 Homo sapiens 40S ribosomal protein S27-like Proteins 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000002452 interceptive effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000001235 sensitizing effect Effects 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- BDUHCSBCVGXTJM-IZLXSDGUSA-N Nutlin-3 Chemical compound CC(C)OC1=CC(OC)=CC=C1C1=N[C@H](C=2C=CC(Cl)=CC=2)[C@H](C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-IZLXSDGUSA-N 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 229940009456 adriamycin Drugs 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000003080 antimitotic agent Substances 0.000 claims 2
- 230000008512 biological response Effects 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims 2
- 229960000752 etoposide phosphate Drugs 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 238000001794 hormone therapy Methods 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 150000003057 platinum Chemical class 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77851906P | 2006-03-02 | 2006-03-02 | |
| PCT/SG2007/000058 WO2007100305A1 (en) | 2006-03-02 | 2007-03-01 | Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding rps27l protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009528346A JP2009528346A (ja) | 2009-08-06 |
| JP2009528346A5 true JP2009528346A5 (https=) | 2010-04-15 |
Family
ID=38459335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557241A Pending JP2009528346A (ja) | 2006-03-02 | 2007-03-01 | Ｒｐｓ２７ｌタンパク質をコードする核酸の活性を調節することによる癌治療に対する細胞の感作 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090137517A1 (https=) |
| EP (1) | EP1996206A4 (https=) |
| JP (1) | JP2009528346A (https=) |
| AU (1) | AU2007221503A1 (https=) |
| TW (1) | TW200800236A (https=) |
| WO (1) | WO2007100305A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2010792B1 (en) | 2006-04-26 | 2015-03-25 | Litens Automotive Partnership | One-way isolator for high torque devices |
| JP5436786B2 (ja) * | 2008-03-06 | 2014-03-05 | オリンパス株式会社 | 細胞周期計測方法 |
| US20110023156A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Feline genome editing with zinc finger nucleases |
| US20110023150A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of genes associated with schizophrenia in animals |
| US20110016539A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of neurotransmission-related genes in animals |
| US20110023154A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Silkworm genome editing with zinc finger nucleases |
| US20110023148A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of addiction-related genes in animals |
| US20110023140A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Rabbit genome editing with zinc finger nucleases |
| US20110023143A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of neurodevelopmental genes in animals |
| US20110023152A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of cognition related genes in animals |
| US20110023151A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genome editing of abc transporters |
| US20110030072A1 (en) * | 2008-12-04 | 2011-02-03 | Sigma-Aldrich Co. | Genome editing of immunodeficiency genes in animals |
| US20110016543A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genomic editing of genes involved in inflammation |
| US20110023153A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in alzheimer's disease |
| US20110016541A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of sensory-related genes in animals |
| US20110016546A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Porcine genome editing with zinc finger nucleases |
| US20110023139A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in cardiovascular disease |
| US20110023144A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
| US20110023149A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in tumor suppression in animals |
| US20110023158A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Bovine genome editing with zinc finger nucleases |
| US20110023141A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved with parkinson's disease |
| US20110023145A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in autism spectrum disorders |
| US20110016540A1 (en) * | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of genes associated with trinucleotide repeat expansion disorders in animals |
| US20110023147A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of prion disorder-related genes in animals |
| US20110023146A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in secretase-associated disorders |
| JP2014513520A (ja) * | 2010-12-29 | 2014-06-05 | シグマ−アルドリッチ・カンパニー、エルエルシー | Ａｄｍｅおよび毒物学的プロセスに関与するタンパク質の乱された発現を有する細胞 |
| WO2018124118A1 (ja) * | 2016-12-27 | 2018-07-05 | 住友化学株式会社 | 人工多能性幹細胞の評価方法及び選抜方法、並びに人工多能性幹細胞の製造方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2568732A1 (en) * | 2004-06-03 | 2005-12-15 | Bayer Healthcare Ag | Methods for predicting and monitoring response to cancer therapy |
| CN1980681A (zh) * | 2004-07-09 | 2007-06-13 | 新加坡科技研究局 | GSK－3β的调节及治疗增殖性病变的方法 |
-
2007
- 2007-03-01 WO PCT/SG2007/000058 patent/WO2007100305A1/en not_active Ceased
- 2007-03-01 AU AU2007221503A patent/AU2007221503A1/en not_active Abandoned
- 2007-03-01 US US12/281,423 patent/US20090137517A1/en not_active Abandoned
- 2007-03-01 EP EP07716150A patent/EP1996206A4/en not_active Withdrawn
- 2007-03-01 JP JP2008557241A patent/JP2009528346A/ja active Pending
- 2007-03-02 TW TW096107084A patent/TW200800236A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009528346A5 (https=) | ||
| JP7431891B2 (ja) | 化学的に修飾されたガイドｒｎａを使用する高特異性ゲノム編集 | |
| Zhou et al. | Theranostic dnazymes | |
| JP2021531022A5 (https=) | ||
| Lee et al. | GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors | |
| Kullak-Ublick et al. | Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells | |
| CN105683377B (zh) | 呼吸疾病相关基因特异性siRNA、含有siRNA的双螺旋寡RNA结构、含有它们的组合物用于预防或治疗呼吸疾病 | |
| US20160215293A1 (en) | Una oligomer active structures for therapeutic agents | |
| WO2007144985A1 (ja) | Ｒｐｎ２遺伝子発現抑制剤の用途 | |
| EA019939B1 (ru) | МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ | |
| EA015570B1 (ru) | Фармацевтическая композиция | |
| JP2008278784A (ja) | １本鎖環状ｒｎａおよびその製造方法 | |
| TW202020156A (zh) | 用於治療原發性高草酸尿症第1型(ph1)之羥酸氧化酶1(hao1)基因編輯之組合物及方法 | |
| JP4274831B2 (ja) | シス・エレメントのデコイを用いる抗ガン剤 | |
| Wang et al. | A self-assembled peptide nucleic acid–microRNA nanocomplex for dual modulation of cancer-related microRNAs | |
| Hu et al. | RNA-based therapies in kidney diseases | |
| JPWO2010024262A1 (ja) | トランスフェクション剤 | |
| US8748592B1 (en) | siRNA for inhibition of OTUB1 expression and pharmaceutical composition containing the same | |
| ES2280098T3 (es) | Oligonucleotidos antisentido contra timidilato sintasa. | |
| US20150140020A1 (en) | Pharmaceutical composition for treating adverse reactions due to administration of spiegelmers | |
| WO2005067632A3 (en) | Lipid compositions and use thereof | |
| Hu et al. | Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma | |
| CN104169422A (zh) | 功能性核酸分子的构建方法和该方法中使用的核酸组合物 | |
| CN112618699A (zh) | 一种能够提供治疗有效量的白介素10的试剂及其抗肿瘤应用 | |
| EP4396347B1 (en) | Chimeric complex and therapeutic uses thereof |